1
0
0
Virologisch-Wissenschaftliches Kolloquium | Universitätsklinikum...
www.medizin.uni-tuebingen.de
Virologisch-Wissenschaftliches Kolloquium. Dr. Mathias Lichterfeld: Selection of HIV-1 reservoir cells during antiretroviral therapy. › veranstaltung
An inside look at how the elite control HIV | EurekAlert! Science News
www.eurekalert.org
Although most HIV-infected individuals progress quickly from infection to immunodeficiency, a small subset survive for long periods without developing...
Infektionen bei Neugeborenen: Frühe Therapie könnte HIV zurückdrängen
www.tagesspiegel.de
· Das schreibt ein Team um Mathias Lichterfeld vom Brigham and Women's Hospital in Boston im Fachblatt „Science Translational Medicine“.
The role of dendritic cells in keeping HIV in check without drugs
www.bionity.com
The role of dendritic cells in keeping HIV in check without drugs. 16-Jun Mathias Lichterfeld, Ragon Institute of MGH, MIT and Harvard, USA; ...
Author: Mathias Lichterfeld - PubMed | Infodoctor
en.infodoctor.org
Latest Publications. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Coauthors. Seiss, Katherine · Rosenberg, Eric S · Yu, Xu G · Pereyra, ...
Reactivation of latent HIV moves shock-and-kill treatments ...
ideas.repec.org
von M Lichterfeld · · Zitiert von: 12 — Mathias Lichterfeld. Registered: Abstract. HIV-1 can evade the immune system by hiding out in a dormant form. › nat › nature
HIV Grand Rounds from the Perelman School of Medicine at ...
www.viraled.com
— Presenter: Mathias Lichterfeld, MD, PhD. Date/Time: Thursday, February 4, at 12:00 PM EST. Topic: Elite controllers as a model for a ... › contact
Comprehensive longitudinal characterization of HIV
biblio.ugent.be
von M Kiselinova · — Kiselinova, Maja, Ward De Spiegelaere, Maria Jose Buzon, Eva Malatinková, Mathias Lichterfeld, and Linos Vandekerckhove › publication
HIV-1 Latency - Google Books
books.google.de
This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing...
Mathias Lichterfeld, M.D., Ph.D. Massachusetts General Hospital An...
dokumen.tips
Slide 1Mathias Lichterfeld, M.D., Ph.D. Massachusetts General Hospital An intrinsic inhibitor of p-TEFb and HIV-1 transcriptional elongation in CD4 T cells...
Documentation: Herrenhausen Nature Symposium "HIV Immunity and...
www.volkswagenstiftung.de
During the internationalen Nature Herrenhausen Symposium on November 2-3, 2017, current aspects of HIV infection, immunity, persistence and eradication...
Dias nummer 1 - Virology Education
regist2.virology-education.com
Clinical HIV-1 eradication studies. Mathias Lichterfeld, M. D., Ph. D. Massachusetts General Hospital. Harvard Medical School. No disclosures. Page 2. H. IV. R. N. A. (cps/m. L. ) 50. Years on cART Slide courtesy of Javier Martinez-Picado/Sharon Lewin. Plasma single copy assay. Cell associated HIV DNA. Infectious ...
Reactivation of latent HIV-1 in central memory CD4+T cells through...
retrovirology.biomedcentral.com
Camille L Novis, Nancie M Archin, Maria J Buzon, Eric Verdin, June L Round, Mathias Lichterfeld, David M Margolis, Vicente Planelles and Alberto Bosque*.
Tumor suppressor blocks viral growth in natural HIV controllers
www.sciencedaily.com
Elevated levels of p21, a protein best known as a cancer fighter, may be involved in the ability of a few individuals to control HIV infection with their...
Elite controllers block integration of HIV DNA into host genome
www.sciencedaily.com
Alone among those infected with HIV-1, so-called elite controllers spontaneously maintain undetectable levels of viral replication even absent the benefit of...
Study identifies population of stem-like cells where HIV persists in...
www.sciencedaily.com
Now investigators may have found where HIV persists in the bodyin spite of antiviral treatment -- in a small group of recently identified T cells with...
HIV-1 Latency | SpringerLinklink.springer.com › book
link.springer.com
Guido Silvestri; Mathias Lichterfeld. Offers new insights into the fascinating area of HIV latency and persistence from multiple perspectives and scientific ...
HIV-1 Latency | SpringerLink
link.springer.com
von G Silvestri · Zitiert von: 1 — Guido Silvestri,; Mathias Lichterfeld. Offers new insights into the fascinating area of HIV latency and persistence from multiple perspectives and ... › book
Wikipedia: Mälu-T-rakud – Vikipeedia
... June L Round, Mathias Lichterfeld, David M Margolis, Vicente Planelles, Alberto Bosque, Reactivation of latent HIV-1 in central memory CD4+ T cells through ...
HIV-1 persistence in CD4+ T cells with stem cell–like properties |...
www.nature.com
Brief Communication
Immunity: Why Can’t HIV Be Cured? Scientists Find the Key Mechanism!...
www.creativebiomart.net
... that these HIV-infected cells can upregulate anti-apoptotic molecules to maintain their long-term survival,” said Mathias Lichterfeld, Ph.D., ...
Mathias Lichterfeld, M.D., Ph.D. Massachusetts General Hospitalwww.slideserve.com › isaura › mathias-lichterfeld-m...
www.slideserve.com
· An intrinsic inhibitor of p-TEFb and HIV-1 transcriptional elongation in CD4 T cells from elite controllers. Mathias Lichterfeld, M.D. ...
UNL | Center for Biotechnology | Events
events.unl.edu
“Cellular reservoirs for HIV-1 long-term persistence despite antiretroviral therapy, ” will be presented by Dr. Mathias Lichterfeld, Massachusetts ...
A Pilot Clinical Trial for HIV-1 Eradication - Mathias Lichterfeld
grantome.com
Although HIV-1 replication can be effectively suppressed with currently existing antiretroviral drugs, infection with HIV-1 remains incurable. This is...
Broad activation of latent HIV-1 in vivo - Research - Aarhus...
pure.au.dk
... and Karen Byth and Robert Lanfear and Ajantha Solomon and James McMahon and Sean Harrington and Maria Buzon and Mathias Lichterfeld and Denton, ...
Day Four | University of Maryland School of Medicine
www.ihv.org
Presentation Title: Distinct Chromosomal Positions of Intact HIV-1 proviruses. Speaker: Mathias Lichterfeld, MD, Ragon Institute of MGH, MIT and Harvard, US.
Does stopping and then re-starting HIV treatment harm the patient? –...
sciworthy.com
Caroline, our resident HIV expert, updates us on some new knowledge about what happens when HIV positive patients stop and restart their medications. Is this a...
"Treatment of HIV-Infected Individuals with the Histone ...
digitalcommons.unomaha.edu
von CR Brinkmann · · Zitiert von: 16 — Mathias Lichterfeld, MIT and Harvard · Xu Yu, MIT and Harvard · Ole Schmeltz Søgaard, Aarhus University · Charles Dinarello, University of Colorado › ...
BEAT-HIV Members - Beat HIV Beat HIV
beat-hiv.org
Katherine J. Bar, M.D., Jay Kostman, M.D., Waheedah Shabazz-El. Michael R. Betts, Ph.D. Edmundo Kraiselburd, Ph.D. George Shaw, M.D., Ph.D. Joel Blankson, M.D., Ph.D. Qingsheng Li, Ph.D. Pamela Shaw, Ph.D. Frederic D. Bushman, Ph.D. Mathias Lichterfeld, M.D., Louise C. Showe, Ph.D. Maria Jose Buzon Gomez, ...
Elite Controllers Block Integration of HIV DNA Into Host Genome
www.infectioncontroltoday.com
undefined
A Possible Sterilizing Cure of HIV-1 Infection Without Stem ...
www.acpjournals.org
von G Turk · · Zitiert von: 10 — ... PhD,; Robert Siliciano, MD,; Janet Siliciano, PhD,; Mathias Lichterfeld, MD, PhD†,; Natalia Laufer, MD, PhD†, and; Xu G. Yu, MD, MSc†. › abs
Engineering professor co-authors Nature Medicine paper on HIV
www1.udel.edu
Zurakowski's co-authors include Mathias Lichterfeld, the paper's lead author, and researchers from Massachusetts General Hospital (MGH); ...
JCI - Clonal expansion of genome-intact HIV-1 in functionally...
www.jci.org
Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4 T cells · Guinevere Q. Lee, … , Xu G. Yu, Mathias Lichterfeld.
HIV-1 Latency - Ghent University Library
lib.ugent.be
HIV-1 Latency [electronic resource] / edited by Guido Silvestri, Mathias Lichterfeld. ISBN: ; Author: Silvestri, Guido. editor. (Editor) (role)http ...
A Prominent Role for Innate Immunity in Eradicating HIV — Countdown...
www.curecountdown.org
Dr. Mathias Lichterfeld. Most animal and test tube models for elimination of latent HIV infection—the major impediment to a cure—suggest that ...
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients...
clinicaltrials.gov
Responsible Party: Mathias Lichterfeld, Associate Professor of Medicine, Massachusetts General Hospital. ClinicalTrials.gov Identifier ...
IAS Towards an HIV Cure Symposium, 29th-30th June 2013, Kuala Lumpur
www.natap.org
Mathias Lichterfeld of the Massachusetts General Hospital proposed that latent HIV-1 infection was driven by the host factor beta-catenin in a relatively new type ...
Broad activation of latent HIV-1 in vivo — Macquarie University
researchers.mq.edu.au
Kirston Barton, Bonnie Hiener, Maria Buzon, Mathias Lichterfeld, Paul W. Denton, Rikke Olesen, Lars Østergaard, Martin Tolstrup, Sharon R. Lewin, Ole ...
Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4...
pure.au.dk
... Ribavirin Reduces CD4 T-Cell-Associated HIV-1 DNA in HIV-1/Hepatitis C Virus-Coinfected Patients",. author = "Hong Sun and Buzon, {Maria J} and Amy Shaw and Berg, {Randi Karteebahn} and Yu, {Xu G} and Sara Ferrando-Martinez and Manuel Leal and Ezequiel Ruiz-Mateos and Mathias Lichterfeld",. year = "2013",.
Alle Infos zum Namen "Mathias Lichterfeld"
Verwandte Suchanfragen zu Mathias Lichterfeld
| Guido Silvestri Rafael Nowak |
Person "Lichterfeld" (1) Vorname "Mathias" (19244) Name "Lichterfeld" (84) |
sortiert nach Relevanz / Datum